Breaking News

RHHBY

Roche

29
May
02
Jun
01
Jul
02
Aug

05/19/23 Piper Sandler: Regeneron Q1 Eylea miss 'not about share, says Piper Sandler

05/08/23 Guggenheim: Regeneron price target lowered to $935 from $960 at Guggenheim

04/10/23 BofA: BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone'

03/27/23 Barclays: Roche downgraded to Equal Weight from Overweight at Barclays

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Recommendations	Regeneron Q1 Eylea miss 'not about share, says Piper Sandler » 08:42 05/19/23 05/19 08:42 05/19/23 08:42 REGN Regeneron $747.30 / -3.025 (-0.40%) , RHHBY Roche $39.59 / -0.23 (-0.58%) Piper Sandler analyst… Piper Sandler analyst Christopher Raymond highlights a new Spherix ophthalmology survey in "the aftermath of another down quarter for Eylea," reporting that the survey work indicates that Eylea "remains the clear intravitreal category leader in nAMD" with 42% patient share and Vabysmo still holds mid-single digit share despite "all of Roche's fanfare." However, Vabysmo momentum is building and the 8mg aflibercept PDUFA "an't come soon enough," added the analyst, who "increasingly" believes Regeneron (REGN) has "very little margin for error with regard to the high dose launch." Piper maintains an Overweight rating and $850 price target on Regeneron shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY REGN RHHBY Roche $39.59 / -0.23 (-0.58%) 05/17/23 Genentech announces fenebrutinib study met primary, secondary endpoint 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche REGN Regeneron $747.30 / -3.025 (-0.40%) 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims 05/18/23 Regeneron 'applauds' Supreme Court's striking down Amgen's patent claims 05/02/23 Regeneron to highlight new, updates data at ASCO 04/17/23 Regeneron announces retirement of board chair REGN RHHBY REGN Regeneron $747.30 / -3.025 (-0.40%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 05/05/23 Morgan Stanley Regeneron price target raised to $927 from $880 at Morgan Stanley 05/05/23 SVB Securities Regeneron price target lowered to $895 from $976 at SVB Securities 05/03/23 Truist Regeneron price target raised to $1,050 from $856 at Truist RHHBY Roche $39.59 / -0.23 (-0.58%) 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham RHHBY REGN RHHBY Roche $39.59 / -0.23 (-0.58%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year REGN Regeneron $747.30 / -3.025 (-0.40%) 05/04/23 Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56 02/03/23 Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03 02/02/23 Notable companies reporting before tomorrow's open RHHBY REGN RHHBY Roche $39.59 / -0.23 (-0.58%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports REGN Regeneron $747.30 / -3.025 (-0.40%) 05/17/23 Regeneron CEO backs regulators attempt to block Amgen deal, FT reports RHHBY REGN RHHBY Roche $39.59 / -0.23 (-0.58%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today REGN Regeneron $747.30 / -3.025 (-0.40%) 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/27/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 05/19/23 ATS 2023 International Conference 06/06/23 2023 ASCO Annual Meeting 00:00 Today PDUFA Date for SRP-9001 06/27/23 PDUFA Date for Eylea 07/01/23 PDUFA Date for Glofitamab 08/20/23 PDUFA Date for Pozelimab 06/09/23 Regeneron Pharmaceuticals REGN REGN Regeneron $747.30 / -3.025 (-0.40%) 03/23/23 Early notable gainers among liquid option names on March 23rd
Hot Stocks	Genentech announces fenebrutinib study met primary, secondary endpoint » 05:23 05/17/23 05/17 05:23 05/17/23 05:23 RHHBY Roche $39.31 / -0.48 (-1.21%) Genentech, a member of… Genentech, a member of Roche, announced results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis, or RMS. The study met its primary and secondary endpoints, showing oral fenebrutinib significantly reduced magnetic resonance imaging, or MRI, markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib to be potent and highly selective, and it is the only reversible inhibitor currently in Phase III trials for MS. Fenebrutinib significantly reduced the total number of new gadolinium-enhancing T1 brain lesions compared to placebo, the primary endpoint of the trial. Additionally, fenebrutinib significantly reduced the total number of new or enlarging T2 brain lesions compared to placebo, a secondary endpoint. Furthermore, a higher proportion of patients treated with fenebrutinib were free from any new gadolinium-enhancing T1 brain lesions and new or enlarging T2-weighted brain lesions compared to placebo. T1 lesions, as measured by MRI, are a marker of active inflammation and T2 lesions represent the amount of disease burden or lesion load. The safety profile of fenebrutinib was consistent with previous and ongoing fenebrutinib clinical trials across more than 2,400 people to date. There were no new safety concerns identified in the FENopta study. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $39.31 / -0.48 (-1.21%) 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting RHHBY Roche $39.31 / -0.48 (-1.21%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham RHHBY Roche $39.31 / -0.48 (-1.21%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year RHHBY Roche $39.31 / -0.48 (-1.21%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports RHHBY Roche $39.31 / -0.48 (-1.21%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab
Conference/Events	Capital One biotech analysts to hold an analyst/industry conference call » 07:50 05/12/23 05/12 07:50 05/12/23 07:50 RHHBY Roche $39.56 / +0.01 (+0.03%) , LLY Eli Lilly $434.52 / -0.26 (-0.06%) , AZN AstraZeneca $74.74 / -0.145 (-0.19%) , ARVN Arvinas $22.88 / -1.335 (-5.51%) , OLMA Olema Oncology $6.81 / +0.16 (+2.41%) Biotech Analyst Jallah,… Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 1 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 Olema announces interim results from ongoing Phase 1b/2 study of OP-1250 12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/03/23 Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target 05/03/23 Eli Lilly TRAILBLAZER-ALZ 2 met primary endpoint, all secondary endpoints 05/01/23 Eli Lilly announces secondary analysis from lebrikizumab study 04/27/23 Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/10/23 AstraZeneca's Ultomiris approved in EU for adults with NMOSD 05/09/23 AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death 05/08/23 AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients 05/05/23 FibroGen announces MATTERHORN study did not meet primary efficacy endpoint ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas expects cash to fund requirements into 2026 04/03/23 Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors RHHBY LLY AZN ARVN OLMA RHHBY Roche $39.56 / +0.01 (+0.03%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/04/23 BMO Capital Eli Lilly price target raised to $505 from $430 at BMO Capital 05/04/23 BofA Biogen price target raised to $320 from $300 at BofA 05/04/23 JPMorgan Eli Lilly price target raised to $475 from $430 at JPMorgan AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus 04/11/23 Guggenheim AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/08/23 Stifel Arvinas price target lowered to $72 from $75 at Stifel 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 H.C. Wainwright Olema Oncology price target raised to $17 from $14 at H.C. Wainwright 05/10/23 Capital One Olema Oncology updates in line with expectations, says Capital One 05/10/23 H.C. Wainwright Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright 05/05/23 Capital One Capital One starts Olema at Buy, sees 200% potential upside RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/09/23 Olema Oncology reports Q1 EPS (70c), consensus (66c) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) LLY Eli Lilly $434.52 / -0.26 (-0.06%) 04/27/23 Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55 04/27/23 Eli Lilly reports Q1 EPS $1.62, consensus $1.73 04/26/23 Notable companies reporting before tomorrow's open AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas reports Q1 EPS ($1.54), consensus ($1.51) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) RHHBY LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports LLY Eli Lilly $434.52 / -0.26 (-0.06%) 04/24/23 Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report 04/12/23 Sanders to call CEOs of largest insulin makers to testify, STAT says 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports 04/10/23 Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' RHHBY OLMA LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/03/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street This Morning 05/03/23 Fly Intel: Pre-market Movers 04/27/23 What You Missed On Wall Street On Thursday AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning 05/12/23 Biotechnology 06/28/23 Biotech/Biopharma 05/19/23 ATS 2023 International Conference 05/23/23 9th Annual Berenberg European Conference 2023 08/08/23 Eli Lilly - LLY 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab 12/22/23 PDUFA Date for Eplontersen 06/15/23 Arvinas, Inc. 06/15/23 Olema Pharmaceuticals, Inc. LLY AZN LLY Eli Lilly $434.52 / -0.26 (-0.06%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th
Conference/Events	Capital One biotech analysts to hold an analyst/industry conference call » 04:55 05/12/23 05/12 04:55 05/12/23 04:55 RHHBY Roche $39.56 / +0.01 (+0.03%) , LLY Eli Lilly $434.52 / -0.26 (-0.06%) , AZN AstraZeneca $74.74 / -0.145 (-0.19%) , ARVN Arvinas $22.88 / -1.335 (-5.51%) , OLMA Olema Oncology $6.81 / +0.16 (+2.41%) Biotech Analyst Jallah,… Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 1 pm. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 Olema announces interim results from ongoing Phase 1b/2 study of OP-1250 12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/03/23 Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target 05/03/23 Eli Lilly TRAILBLAZER-ALZ 2 met primary endpoint, all secondary endpoints 05/01/23 Eli Lilly announces secondary analysis from lebrikizumab study 04/27/23 Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/10/23 AstraZeneca's Ultomiris approved in EU for adults with NMOSD 05/09/23 AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death 05/08/23 AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients 05/05/23 FibroGen announces MATTERHORN study did not meet primary efficacy endpoint ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas expects cash to fund requirements into 2026 04/03/23 Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors RHHBY LLY AZN ARVN OLMA RHHBY Roche $39.56 / +0.01 (+0.03%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/04/23 BMO Capital Eli Lilly price target raised to $505 from $430 at BMO Capital 05/04/23 BofA Biogen price target raised to $320 from $300 at BofA 05/04/23 JPMorgan Eli Lilly price target raised to $475 from $430 at JPMorgan AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus 04/11/23 Guggenheim AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/08/23 Stifel Arvinas price target lowered to $72 from $75 at Stifel 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 H.C. Wainwright Olema Oncology price target raised to $17 from $14 at H.C. Wainwright 05/10/23 Capital One Olema Oncology updates in line with expectations, says Capital One 05/10/23 H.C. Wainwright Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright 05/05/23 Capital One Capital One starts Olema at Buy, sees 200% potential upside RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/09/23 Olema Oncology reports Q1 EPS (70c), consensus (66c) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) LLY Eli Lilly $434.52 / -0.26 (-0.06%) 04/27/23 Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55 04/27/23 Eli Lilly reports Q1 EPS $1.62, consensus $1.73 04/26/23 Notable companies reporting before tomorrow's open AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas reports Q1 EPS ($1.54), consensus ($1.51) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) RHHBY LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports LLY Eli Lilly $434.52 / -0.26 (-0.06%) 04/24/23 Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report 04/12/23 Sanders to call CEOs of largest insulin makers to testify, STAT says 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports 04/10/23 Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' RHHBY OLMA LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations LLY Eli Lilly $434.52 / -0.26 (-0.06%) 05/03/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street This Morning 05/03/23 Fly Intel: Pre-market Movers 04/27/23 What You Missed On Wall Street On Thursday AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning 05/12/23 Biotechnology 06/28/23 Biotech/Biopharma 05/19/23 ATS 2023 International Conference 05/23/23 9th Annual Berenberg European Conference 2023 08/08/23 Eli Lilly - LLY 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab 12/22/23 PDUFA Date for Eplontersen 06/15/23 Arvinas, Inc. 06/15/23 Olema Pharmaceuticals, Inc. LLY AZN LLY Eli Lilly $434.52 / -0.26 (-0.06%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th
Conference/Events	Capital One biotech analysts to hold an analyst/industry conference call » 22:59 05/11/23 05/11 22:59 05/11/23 22:59 RHHBY Roche $39.56 / +0.01 (+0.03%) , LLY Eli Lilly $435.65 / -0.26 (-0.06%) , AZN AstraZeneca $74.74 / -0.145 (-0.19%) , ARVN Arvinas $22.88 / -1.335 (-5.51%) , OLMA Olema Oncology $6.81 / +0.16 (+2.41%) Biotech Analyst Jallah,… Biotech Analyst Jallah, along with a Key Opinion Leader, discuss drugs in development for HR+ HER2- Breast Cancer including ones from Roche, Lilly, AstraZeneca, Arvinas and Olema on an Analyst/Industry conference call to be held on May 12 at 8 am. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 Olema announces interim results from ongoing Phase 1b/2 study of OP-1250 12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 LLY Eli Lilly $435.65 / -0.26 (-0.06%) 05/03/23 Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target 05/03/23 Eli Lilly TRAILBLAZER-ALZ 2 met primary endpoint, all secondary endpoints 05/01/23 Eli Lilly announces secondary analysis from lebrikizumab study 04/27/23 Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/10/23 AstraZeneca's Ultomiris approved in EU for adults with NMOSD 05/09/23 AstraZeneca says Farxiga extended in U.S. to reduce risk of cardiovascular death 05/08/23 AstraZeneca reports Koselugo approved in China for inoperable PN in NF1 patients 05/05/23 FibroGen announces MATTERHORN study did not meet primary efficacy endpoint ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas expects cash to fund requirements into 2026 04/03/23 Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors RHHBY LLY AZN ARVN OLMA RHHBY Roche $39.56 / +0.01 (+0.03%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham LLY Eli Lilly $435.65 / -0.26 (-0.06%) 05/04/23 BMO Capital Eli Lilly price target raised to $505 from $430 at BMO Capital 05/04/23 BofA Biogen price target raised to $320 from $300 at BofA 05/04/23 JPMorgan Eli Lilly price target raised to $475 from $430 at JPMorgan AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus 04/11/23 Guggenheim AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/08/23 Stifel Arvinas price target lowered to $72 from $75 at Stifel 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/11/23 H.C. Wainwright Olema Oncology price target raised to $17 from $14 at H.C. Wainwright 05/10/23 Capital One Olema Oncology updates in line with expectations, says Capital One 05/10/23 H.C. Wainwright Olema Oncology price target lowered to $14 from $15 at H.C. Wainwright 05/05/23 Capital One Capital One starts Olema at Buy, sees 200% potential upside RHHBY OLMA LLY AZN ARVN RHHBY Roche $39.56 / +0.01 (+0.03%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/09/23 Olema Oncology reports Q1 EPS (70c), consensus (66c) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) LLY Eli Lilly $435.65 / -0.26 (-0.06%) 04/27/23 Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55 04/27/23 Eli Lilly reports Q1 EPS $1.62, consensus $1.73 04/26/23 Notable companies reporting before tomorrow's open AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 ARVN Arvinas $22.88 / -1.335 (-5.51%) 05/05/23 Arvinas reports Q1 EPS ($1.54), consensus ($1.51) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) RHHBY LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports LLY Eli Lilly $435.65 / -0.26 (-0.06%) 04/24/23 Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report 04/12/23 Sanders to call CEOs of largest insulin makers to testify, STAT says 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports 04/10/23 Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says 12/09/22 AstraZeneca says Dato-DXd 'continued to demonstrate encouraging responses' RHHBY OLMA LLY AZN RHHBY Roche $39.56 / +0.01 (+0.03%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today OLMA Olema Oncology $6.81 / +0.16 (+2.41%) 05/05/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations LLY Eli Lilly $435.65 / -0.26 (-0.06%) 05/03/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street This Morning 05/03/23 Fly Intel: Pre-market Movers 04/27/23 What You Missed On Wall Street On Thursday AZN AstraZeneca $74.74 / -0.145 (-0.19%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning 06/28/23 Biotech/Biopharma 05/11/23 Berenberg Diagnostics Conference 2023 05/19/23 ATS 2023 International Conference 05/23/23 9th Annual Berenberg European Conference 2023 08/08/23 Eli Lilly - LLY 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab 12/22/23 PDUFA Date for Eplontersen 06/15/23 Arvinas, Inc. 06/15/23 Olema Pharmaceuticals, Inc. LLY AZN LLY Eli Lilly $435.65 / -0.26 (-0.06%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th AZN AstraZeneca $74.74 / -0.145 (-0.19%) 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th
Periodicals	BioNTech data was reported in June 2022, Reuters reports » 12:33 05/10/23 05/10 12:33 05/10/23 12:33 BNTX BioNTech $104.50 / -0.215 (-0.21%) , RHHBY Roche $39.80 / -0.16 (-0.40%) A personalized treatment… A personalized treatment based on messenger RNA by BioNTech (BNTX) may bode well for the future of fighting pancreatic cancer, with results of a trial showing that half of the 16 trial participants, who had undergone surgery to remove their tumor, had developed T cells that can potentially recognize cancerous cells and stop them from re-emerging, Reuters' Ludwig Burger reports, citing scientific journal Nature. The publication notes that BioNTech, which co-developed the treatment with Roche's (RHHBY) Genentech, first reported the data in June 2022. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY BNTX RHHBY Roche $39.80 / -0.16 (-0.40%) 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting BNTX BioNTech $104.50 / -0.215 (-0.21%) 05/08/23 BioNTech sees FY23 CapEx EUR 500M-EUR 600M 05/08/23 BioNTech backs FY23 Covid-19 vaccine revenue ~EUR 5B 04/18/23 FDA clears second bivalent COVID booster for older individuals 04/04/23 Arbutus, Genevant file patent infringement suit against Pfizer, BioNTech BNTX RHHBY BNTX BioNTech $104.50 / -0.215 (-0.21%) 03/30/23 Morgan Stanley BioNTech could be up 20%-30% if PCV readout impresses, says Morgan Stanley 03/28/23 Morgan Stanley BioNTech price target lowered to $150 from $216 at Morgan Stanley 03/28/23 Canaccord BioNTech price target raised to $203 from $191 at Canaccord 03/28/23 TD Cowen BioNTech price target lowered to $130 from $145 at TD Cowen RHHBY Roche $39.80 / -0.16 (-0.40%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham RHHBY BNTX RHHBY Roche $39.80 / -0.16 (-0.40%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year BNTX BioNTech $104.50 / -0.215 (-0.21%) 05/08/23 BioNTech reports Q1 EPS EUR 2.05 vs. EUR 14.24 last year 03/27/23 BioNTech reports Q4 EPS EUR 9.26 vs. EUR 12.18 last year RHHBY BNTX RHHBY Roche $39.80 / -0.16 (-0.40%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports BNTX BioNTech $104.50 / -0.215 (-0.21%) 05/10/23 BioNTech pancreatic cancer vaccine 'shows promise' in small trial, NYT says 03/21/23 FDA moving towards authorizing second omicron booster, WSJ reports 01/09/23 Moderna considering $110-$130 for COVID shot, similar to Pfizer's, WSJ says RHHBY BNTX RHHBY Roche $39.80 / -0.16 (-0.40%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today BNTX BioNTech $104.50 / -0.215 (-0.21%) 05/08/23 Fly Intel: Pre-market Movers 03/30/23 Biotech Alert: Searches spiking for these stocks today 03/27/23 Fly Intel: Pre-market Movers 03/21/23 What You Missed On Wall Street On Tuesday 05/11/23 Berenberg Diagnostics Conference 2023 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab
Hot Stocks	Genentech announces FDA acceptance of Vabysmo sBLA » 05:44 05/09/23 05/09 05:44 05/09/23 05:44 RHHBY Roche $39.96 / +0.17 (+0.43%) Genentech, a member of… Genentech, a member of Roche, announced that the FDA has accepted the company's supplemental Biologics License Application, or sBLA, for Vabysmo for the treatment of macular edema following retinal vein occlusion, or RVO. The sBLA is based on results from the Phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept. Vabysmo's safety profile was consistent with previous trials. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $39.96 / +0.17 (+0.43%) 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting 04/25/23 Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept RHHBY Roche $39.96 / +0.17 (+0.43%) 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham RHHBY Roche $39.96 / +0.17 (+0.43%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year RHHBY Roche $39.96 / +0.17 (+0.43%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports RHHBY Roche $39.96 / +0.17 (+0.43%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 05/11/23 Berenberg Diagnostics Conference 2023 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab
Recommendations	Regeneron price target lowered to $935 from $960 at Guggenheim » 10:21 05/08/23 05/08 10:21 05/08/23 10:21 REGN Regeneron $752.42 / -8.89 (-1.17%) , RHHBY Roche $39.79 / +0.15 (+0.38%) Guggenheim analyst Yatin… Guggenheim analyst Yatin Suneja lowered the firm's price target on Regeneron (REGN) to $935 from $960 and keeps a Buy rating on the shares following quarterly results. While the temporary copay issues from Q4 have been resolved, Eylea U.S. sales were down on competitive pressures and inventory dynamics, the firm notes. Pressure from Roche's (RHHBY) Vabysmo is growing and likely to persist until HD Eylea is launched, Guggenheim adds. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options RHHBY REGN RHHBY Roche $39.79 / +0.15 (+0.38%) 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting 04/25/23 Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept REGN Regeneron $752.42 / -8.89 (-1.17%) 05/02/23 Regeneron to highlight new, updates data at ASCO 04/17/23 Regeneron announces retirement of board chair 04/17/23 Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting 03/29/23 Regeneron announces EC approved Libtayo in combination with chemotherapy REGN RHHBY REGN Regeneron $752.42 / -8.89 (-1.17%) 05/05/23 Morgan Stanley Regeneron price target raised to $927 from $880 at Morgan Stanley 05/05/23 SVB Securities Regeneron price target lowered to $895 from $976 at SVB Securities 05/03/23 Truist Regeneron price target raised to $1,050 from $856 at Truist 04/20/23 TD Cowen Regeneron price target raised to $885 from $875 at TD Cowen RHHBY Roche $39.79 / +0.15 (+0.38%) 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham 02/27/23 Societe Generale Societe Generale upgrades Roche to Buy, says 'enough is enough' RHHBY REGN RHHBY Roche $39.79 / +0.15 (+0.38%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year REGN Regeneron $752.42 / -8.89 (-1.17%) 05/04/23 Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56 02/03/23 Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03 02/02/23 Notable companies reporting before tomorrow's open RHHBY RHHBY Roche $39.79 / +0.15 (+0.38%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports RHHBY REGN RHHBY Roche $39.79 / +0.15 (+0.38%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today REGN Regeneron $752.42 / -8.89 (-1.17%) 03/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/27/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 05/11/23 Berenberg Diagnostics Conference 2023 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 06/27/23 PDUFA Date for Eylea 07/01/23 PDUFA Date for Glofitamab 08/20/23 PDUFA Date for Pozelimab 06/09/23 Regeneron Pharmaceuticals REGN REGN Regeneron $752.42 / -8.89 (-1.17%) 03/23/23 Early notable gainers among liquid option names on March 23rd

Over a month ago
Hot Stocks	Roche reports CHMP recommends EU approval of fixed-duration Columvi » 12:52 04/26/23 04/26 12:52 04/26/23 12:52 RHHBY Roche $39.85 / +0.2 (+0.50%) Roche announced that the… Roche announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has recommended the approval of Columvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, after two or more lines of systemic therapy. A final decision is expected from the European Commission in the "near future," the company said. "New therapeutic options that are readily and broadly available are urgently needed for people with relapsing diffuse large B-cell lymphoma, which can become fatal without immediate treatment. The CHMP's recommendation for Columvi brings us closer to providing a new, fixed-duration therapy for people with diffuse large B-cell lymphoma that induces early and long-lasting responses," said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events RHHBY Roche $39.85 / +0.2 (+0.50%) 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting 04/25/23 Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept 04/19/23 FDA approves Roche's Polivy in combination with R-CHP RHHBY Roche $39.85 / +0.2 (+0.50%) 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham 02/27/23 Societe Generale Societe Generale upgrades Roche to Buy, says 'enough is enough' RHHBY Roche $39.85 / +0.2 (+0.50%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year RHHBY Roche $39.85 / +0.2 (+0.50%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports RHHBY Roche $39.85 / +0.2 (+0.50%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab
Hot Stocks	Zentalis enters agreements with Foundation Medicine, Roche » 10:07 04/26/23 04/26 10:07 04/26/23 10:07 ZNTL Zentalis $21.57 / -0.21 (-0.96%) , RHHBY Roche $39.85 / +0.2 (+0.50%) The Company announced… The Company announced separate agreements with Foundation Medicine, Inc., an independent affiliate of the Roche Group, and with Roche Diagnostics. The current Foundation Medicine partnership involves global prospective genomic profiling for potential patient enrollment in Zentalis' Phase 2 clinical trial of azenosertib in Cyclin E1 driven high-grade serous ovarian cancer. The companies are also exploring opportunities to develop Foundation Medicine's tissue-based next generation sequencing assay as a companion diagnostic for azenosertib. The Roche Diagnostics agreement is focused on the development of an immunohistochemistry-based clinical trial assay that evaluates Cyclin E1 protein levels and that can potentially identify a broader patient population with high protein expression in the absence of amplification. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events ZNTL RHHBY ZNTL Zentalis $21.57 / -0.21 (-0.96%) 04/26/23 Zentalis to present clinical data from Phase 1b trial of azenosertib 04/17/23 Zentalis announces preclinical data on Cyclin E1 at AACR annual meeting 2023 02/13/23 Zentalis announces appointment of Roth as COO 11/09/22 Zentalis expects cash to fund requirements into 1Q25 RHHBY Roche $39.85 / +0.2 (+0.50%) 04/26/23 Bolt Biotherapeutics to present BDC-1001 trial data at 2023 ASCO meeting 04/25/23 Roche announces Vabysmo data suggests greater retinal drying vs. aflibercept 04/19/23 FDA approves Roche's Polivy in combination with R-CHP 04/16/23 Roche's Genentech announces data from Phase III IMbrave050 study ZNTL RHHBY ZNTL Zentalis $21.57 / -0.21 (-0.96%) 03/15/23 Stifel Zentalis price target lowered to $46 from $55 at Stifel 11/14/22 Wedbush Zentalis price target lowered to $32 from $51 at Wedbush 11/14/22 Wells Fargo Zentalis price target lowered to $46 from $52 at Wells Fargo 11/10/22 Oppenheimer Zentalis price target lowered to $50 from $80 at Oppenheimer RHHBY Roche $39.85 / +0.2 (+0.50%) 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham 02/27/23 Societe Generale Societe Generale upgrades Roche to Buy, says 'enough is enough' ZNTL RHHBY ZNTL Zentalis $21.57 / -0.21 (-0.96%) 03/01/23 Zentalis reports FY22 EPS ($4.48), consensus ($4.60) 11/09/22 Zentalis reports Q3 EPS (96c), consensus ($1.17) RHHBY Roche $39.85 / +0.2 (+0.50%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year 16 May RHHBY RHHBY Roche $39.85 / +0.2 (+0.50%) 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports ZNTL RHHBY ZNTL Zentalis $21.57 / -0.21 (-0.96%) 11/18/22 Sell these stocks now, proven algorithm says 10/30/22 Sell these stocks now, proven algorithm says RHHBY Roche $39.85 / +0.2 (+0.50%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 05/19/23 ATS 2023 International Conference 00:00 Today PDUFA Date for SRP-9001 07/01/23 PDUFA Date for Glofitamab

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial